KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Inventory: 2018-2024

Historic Inventory for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Dec 2024 value amounting to $78.5 million.

  • Alnylam Pharmaceuticals' Inventory fell 0.79% to $75.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.4 million, marking a year-over-year decrease of 0.79%. This contributed to the annual value of $78.5 million for FY2024, which is 11.93% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Inventory stood at $78.5 million for FY2024, which was down 11.93% from $89.1 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Inventory ranged from a high of $129.0 million in FY2022 and a low of $75.2 million during FY2020.
  • Its 3-year average for Inventory is $98.9 million, with a median of $89.1 million in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Inventory spiked by 49.33% in 2022 and then slumped by 30.87% in 2023.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Inventory stood at $75.2 million in 2020, then grew by 14.84% to $86.4 million in 2021, then surged by 49.33% to $129.0 million in 2022, then crashed by 30.87% to $89.1 million in 2023, then declined by 11.93% to $78.5 million in 2024.